Gasc1 Expression To Predict Response To Paclitaxel Plus Cisplatin In Oesophageal Squamous Cell Carcinoma.

e15065 Background: GASC1 is a novel driver oncogene involved in the development of multiple cancers. Our preliminary study reported GASC1 contributed to the occurrence and progression of esophageal squamous cell carcinoma (ESCC). However, it remains unclear if GASC1 contributes to chemoresistance of ESCC. Methods: We evaluated GASC1 expression immunohistochemically in biopsy specimens from 60 patients with ESCC (clinical stag II-‡W ), who received adjuvant chemotherapy with TP regiment, and compared clinical response rate (cRR, including clinical complete response (cCR) and partial response (cPR)), pathological complete response rate (pCRR) and over survival (OS) between the GASC1-positive and GASC1-negative groups. We also studied susceptibility of GASC1-suppressed ESCC cells to TP. Fisher’s exact test was performed for data analyses. P u003c 0.05 was considered to be significant. Results: GASC1 positive expression rate is 50% in ESCC before chemotherapy. The cRR and pCRR in GASC1- negative group were all si...